摘要
[目的]观察苦参素注射液对人肝癌细胞株HepG2/DDP顺铂敏感性的影响,并探讨其机制。[方法]取人耐顺铂肝癌细胞株HepG2/DDP培养,每孔分装1.5×10^(6)个细胞。对照组加入2 mg/L顺铂,低、中、高剂量组分别加入2 mg/L顺铂+0.75 mg/mL苦参素注射液、2 mg/L顺铂+1.5 mg/mL苦参素注射液、2 mg/L顺铂+3 mg/mL苦参素注射液,均继续培养72 h。[结果]培养72 h后,对照组细胞贴壁生长状态良好,3剂量组均可导致细胞株形态学改变;3剂量组可提高增殖抑制率和细胞凋亡率(P<0.05),且高剂量组效果最佳[(25.55±3.24)%、(32.93±3.62)%、(39.32±4.15)%;(26.95±1.58)%、(34.36±3.07)%、(42.46±4.47)%](P<0.05);3剂量组均可降低p-JAK2/JAK2、p-STAT3/STAT3水平(P<0.05),且高剂量组效果最佳[(0.143±0.007)、(0.143±0.010)](P<0.05)。[结论]苦参素注射液可增强人肝癌细胞株HepG2/DDP顺铂化疗敏感性,抑制细胞增殖并促进细胞凋亡,且3 mg/mL苦参素注射液的效果更佳,推测与控制JAK2、STAT3蛋白磷酸化水平有关。
[Objective]To observe the effect of matrine injection on HepG2/DDP to cisplatin sensitivity and its mechanism.[Method]Human cisplatin-resistant hepatocellular carcinoma cell line HepG2/DDP was cultured and subdivided into control group,low,medium and high dose groups.Each group was divided into 5 multiple holes,and each hole had 1.5×10~6 cells.The control group was treated with 2 mg/L cisplatin while the low,middle and high dose groups were treated with 2 mg/L cisplatin+0.75 mg/mL matrine injection,2 mg/L cisplatin+1.5 mg/mL matrine injection,2 mg/L cisplatin+3 mg/mL matrine injection,respectively,for 72 hours.[Result]After 72 hours of culture,the cells in the control group grew well,and the morphology of the cells in the three dose group could be changed;The inhibition rate and apoptosis rate of cells were increased in the 3 dose group(P<0.05),and the results of high dose group were the best[(25.55±3.24)%,(32.93±3.62)%,(39.32±4.15)%;(26.95±1.58)%,(34.36±3.07)%,(42.46±4.47)%](P<0.05).The p-JAK2/JAK2,p-STAT3/STAT3 levels in the three dose groups were decreased(P<0.05),and the results of the high dose group were the best[(0.143±0.007),(0.143±0.010)](P<0.05).[Conclusion]Matrine injection can enhance the chemosensitivity of human hepatocellular carcinoma cell line HepG2/DDP to cisplatin,inhibit cell proliferation and promote cell apoptosis,and the effect of 3 mg/mL matrine injection is best.It is presumed that it is related to control the phosphorylation of JAK2 and STAT3 proteins.
作者
陈丰穗
黄兴华
CHEN Feng-sui;HUANG Xing-hua(Department of Hepatobiliary Disease,The 900th Hospital of the Joint Logistic Support Force of People′s Liberation Army,Fuzhou 350025,China)
出处
《生物技术》
CAS
2022年第2期188-194,共7页
Biotechnology
基金
科技创新联合资金项目(2019Y9044)
解放军联勤保障部队第九〇〇医院杰出青年培育专项(2018Q07)。